Klein Samuel, Fontana Luigi, Young V Leroy, Coggan Andrew R, Kilo Charles, Patterson Bruce W, Mohammed B Selma
Center for Human Nutrition, Washington University School of Medicine, St. Louis 63110, USA.
N Engl J Med. 2004 Jun 17;350(25):2549-57. doi: 10.1056/NEJMoa033179.
Liposuction has been proposed as a potential treatment for the metabolic complications of obesity. We evaluated the effect of large-volume abdominal liposuction on metabolic risk factors for coronary heart disease in women with abdominal obesity.
We evaluated the insulin sensitivity of liver, skeletal muscle, and adipose tissue (with a euglycemic-hyperinsulinemic clamp procedure and isotope-tracer infusions) as well as levels of inflammatory mediators and other risk factors for coronary heart disease in 15 obese women before and 10 to 12 weeks after abdominal liposuction. Eight of the women had normal glucose tolerance (mean [+/-SD] body-mass index, 35.1+/-2.4), and seven had type 2 diabetes (body-mass index, 39.9+/-5.6).
Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent in the subjects with normal glucose tolerance and 28 percent in those with diabetes; those with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P<0.001). Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor alpha, and adiponectin; and did not significantly affect other risk factors for coronary heart disease (blood pressure and plasma glucose, insulin, and lipid concentrations) in either group.
Abdominal liposuction does not significantly improve obesity-associated metabolic abnormalities. Decreasing adipose tissue mass alone will not achieve the metabolic benefits of weight loss.
抽脂术已被提议作为肥胖代谢并发症的一种潜在治疗方法。我们评估了大容量腹部抽脂术对腹部肥胖女性冠心病代谢危险因素的影响。
我们通过正常血糖-高胰岛素钳夹术和同位素示踪剂输注评估了15名肥胖女性在腹部抽脂术前以及术后10至12周时肝脏、骨骼肌和脂肪组织的胰岛素敏感性,以及炎症介质水平和其他冠心病危险因素。其中8名女性糖耐量正常(平均[±标准差]体重指数,35.1±2.4),7名患有2型糖尿病(体重指数,39.9±5.6)。
抽脂术后,糖耐量正常的受试者腹部皮下脂肪组织体积减少了44%,糖尿病患者减少了28%;糖耐量正常者脂肪减少了9.1±3.7 kg(总脂肪减少18±3%,P = 0.002),2型糖尿病患者脂肪减少了10.5±3.3 kg(总脂肪减少19±2%,P<0.001)。抽脂术未显著改变肌肉、肝脏或脂肪组织的胰岛素敏感性(分别通过葡萄糖处置刺激、葡萄糖生成抑制和脂肪分解抑制来评估);未显著改变血浆C反应蛋白、白细胞介素-6、肿瘤坏死因子α和脂联素的浓度;也未显著影响两组中其他冠心病危险因素(血压、血浆葡萄糖、胰岛素和脂质浓度)。
腹部抽脂术并不能显著改善与肥胖相关的代谢异常。仅减少脂肪组织量并不能实现减肥带来的代谢益处。